198 related articles for article (PubMed ID: 12562663)
21. Nail alterations secondary to pactitaxel [corrected] therapy.
Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
[TBL] [Abstract][Full Text] [Related]
22. [Onycholysis due to docetaxel in breast cancer treatment].
Grasland A; Grandjean M; Rist S; Bosquet A; Vinceneux P
Rev Med Interne; 2005 May; 26(5):427-8. PubMed ID: 15893036
[No Abstract] [Full Text] [Related]
23. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity.
Can G; Aydiner A; Cavdar I
Eur J Oncol Nurs; 2012 Jul; 16(3):270-5. PubMed ID: 21784705
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.
Bernstein BJ
Ann Pharmacother; 2000 Nov; 34(11):1332-5. PubMed ID: 11098349
[TBL] [Abstract][Full Text] [Related]
25. Epiphora induced by intermittent docetaxel (taxotere) in patients with non-small cell lung cancer.
Spell DW; Estephan FF; Lin JT; Jones DV
Cancer Invest; 2003; 21(4):550-2. PubMed ID: 14533445
[No Abstract] [Full Text] [Related]
26. Severe nail changes due to Docetaxel treatment.
Rafi L; Friedrich M; Tilgen W; Reichrath J
Eur J Dermatol; 2003; 13(6):610-1. PubMed ID: 14721789
[TBL] [Abstract][Full Text] [Related]
27. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?
Spazzapan S; Crivellari D; Lombardi D; Scuderi C; Magri MD; Veronesi A; Gatti A
J Clin Oncol; 2002 Nov; 20(21):4404-5; author reply 4405. PubMed ID: 12409345
[No Abstract] [Full Text] [Related]
28. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
29. Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel.
Hofer S; Hunziker S; Tornillo L; Ludwig CU
Ann Oncol; 2003 Feb; 14(2):340. PubMed ID: 12562665
[No Abstract] [Full Text] [Related]
30. Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Wasner G; Hilpert F; Schattschneider J; Binder A; Pfisterer J; Baron R
J Neurooncol; 2002 Jun; 58(2):167-74. PubMed ID: 12164689
[TBL] [Abstract][Full Text] [Related]
31. Nail changes during docetaxel containing combination chemotherapy.
Woo IS; Shim KH; Kim GY; Lee MA; Kang JH; Hong YS; Lee KS
Korean J Intern Med; 2004 Jun; 19(2):132-3. PubMed ID: 15366647
[TBL] [Abstract][Full Text] [Related]
32. Inflammation of seborrheic keratoses due to docetaxel treatment.
Chu CY; Yang CH; Chiu HC
Acta Derm Venereol; 2001; 81(4):316-7. PubMed ID: 11720193
[No Abstract] [Full Text] [Related]
33. Reversible hepatic coma possibly induced by docetaxel treatment.
Chen YM; Tsai CM; Perng RP
Lung Cancer; 2001; 31(2-3):347-8. PubMed ID: 11305259
[No Abstract] [Full Text] [Related]
34. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
Hussain S; Anderson DN; Salvatti ME; Adamson B; McManus M; Braverman AS
Cancer; 2000 May; 88(10):2367-71. PubMed ID: 10820360
[TBL] [Abstract][Full Text] [Related]
35. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
Ghetti E; Piraccini BM; Tosti A
J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):459-60. PubMed ID: 12834462
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
37. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Camidge DR; Kunkler IH
Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
[No Abstract] [Full Text] [Related]
38. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Langer-Nitsche C; Lück HJ; Heilmann M
Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
[No Abstract] [Full Text] [Related]
39. [Fulminant hepatocellular necrosis following administration of docetaxel].
Tomassini E; Muhizi J; al Raheb K; Steinbach G; Bemer M; Platini C
Presse Med; 2001 Apr; 30(13):634. PubMed ID: 11346902
[No Abstract] [Full Text] [Related]
40. Taxol and taxotere--current status and future prospects.
Bissett D; Kaye SB
Eur J Cancer; 1993; 29A(9):1228-31. PubMed ID: 8102062
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
